Research Analysts’ Recent Ratings Updates for IQVIA (IQV)

Several brokerages have updated their recommendations and price targets on shares of IQVIA (NYSE: IQV) in the last few weeks:

• 11/3/2025 – IQVIA was downgraded by analysts at Cowen Inc from a “buy” rating to a “hold” rating.
• 11/3/2025 – IQVIA was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating. They now have a $215.00 price target on the stock, up previously from $206.00.
• 11/1/2025 – IQVIA was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/29/2025 – IQVIA had its price target raised by analysts at Stifel Nicolaus from $234.00 to $254.00. They now have a “buy” rating on the stock.
• 10/29/2025 – IQVIA had its price target raised by analysts at UBS Group AG from $225.00 to $250.00. They now have a “buy” rating on the stock.
• 10/29/2025 – IQVIA had its price target raised by analysts at Citigroup Inc. from $200.00 to $230.00. They now have a “neutral” rating on the stock.
• 10/29/2025 – IQVIA was given a new $258.00 price target on by analysts at Robert W. Baird. They now have an “outperform” rating on the stock.
• 10/29/2025 – IQVIA was upgraded by analysts at Baird R W from a “hold” rating to a “strong-buy” rating.
• 10/29/2025 – IQVIA had its price target raised by analysts at JPMorgan Chase & Co. from $177.00 to $255.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – IQVIA had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $265.00 price target on the stock, up previously from $235.00.
• 10/9/2025 – IQVIA was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $235.00 price target on the stock, up previously from $195.00.
• 10/9/2025 – IQVIA was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating.
• 10/8/2025 – IQVIA had its price target raised by analysts at Evercore ISI from $220.00 to $240.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – IQVIA had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/2/2025 – IQVIA had its price target raised by analysts at Barclays PLC from $185.00 to $200.00. They now have an “equal weight” rating on the stock.
• 9/27/2025 – IQVIA had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/9/2025 – IQVIA was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $225.00 price target on the stock, up previously from $195.00.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.